<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN""http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html><head><title>Patent US5641805 - Topical ophthalmic formulations for treating allergic eye diseases - Google Patents</title><script>(function(){(function(){function e(a){this.t={};this.tick=function(a,c,b){var d=void 0!=b?b:(new Date).getTime();this.t[a]=[d,c];if(void 0==b)try{window.console.timeStamp("CSI/"+a)}catch(e){}};this.tick("start",null,a)}var a;window.performance&&(a=window.performance.timing);var f=a?new e(a.responseStart):new e;window.jstiming={Timer:e,load:f};if(a){var c=a.navigationStart,d=a.responseStart;0<c&&d>=c&&(window.jstiming.srt=d-c)}if(a){var b=window.jstiming.load;0<c&&d>=c&&(b.tick("_wtsrt",void 0,c),b.tick("wtsrt_",
"_wtsrt",d),b.tick("tbsd_","wtsrt_"))}try{a=null,window.chrome&&window.chrome.csi&&(a=Math.floor(window.chrome.csi().pageT),b&&0<c&&(b.tick("_tbnd",void 0,window.chrome.csi().startE),b.tick("tbnd_","_tbnd",c))),null==a&&window.gtbExternal&&(a=window.gtbExternal.pageT()),null==a&&window.external&&(a=window.external.pageT,b&&0<c&&(b.tick("_tbnd",void 0,window.external.startE),b.tick("tbnd_","_tbnd",c))),a&&(window.jstiming.pt=a)}catch(g){}})();})();
</script><link rel="stylesheet" href="/patents/css/_4ff636b3d23669b7103f3b3a3a18b4cd/kl_intl_patents_bundle.css" type="text/css" /><script src="/books/javascript/atb_4ff636b3d23669b7103f3b3a3a18b4cd__en.js"></script><script>function googleTranslateElementInit() {new google.translate.TranslateElement({pageLanguage: "en",gaTrack: true,gaId: "UA-27188110-1",multilanguagePage: true});}</script><script src="//translate.google.com/translate_a/element.js?cb=googleTranslateElementInit"></script><meta name="DC.type" content="Patent"><meta name="DC.title" content="Topical ophthalmic formulations for treating allergic eye diseases"><meta name="DC.contributor" content="Eiji Hayakawa" scheme="inventor"><meta name="DC.contributor" content="Masashi Nakakura" scheme="inventor"><meta name="DC.contributor" content="Stella M. Robertson" scheme="inventor"><meta name="DC.contributor" content="John Michael Yanni" scheme="inventor"><meta name="DC.contributor" content="Alcon Laboratories, Inc." scheme="assignee"><meta name="DC.contributor" content="Kyowa Hakko Kogyo Co. Ltd." scheme="assignee"><meta name="DC.date" content="1995-6-6" scheme="dateSubmitted"><meta name="DC.description" content="Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis."><meta name="DC.date" content="1997-6-24" scheme="issued"><meta name="DC.relation" content="EP:0048023:A2" scheme="references"><meta name="DC.relation" content="EP:0214779:A1" scheme="references"><meta name="DC.relation" content="EP:0235796:A2" scheme="references"><meta name="DC.relation" content="US:4871865" scheme="references"><meta name="DC.relation" content="US:4923892" scheme="references"><meta name="DC.relation" content="US:5116863" scheme="references"><meta name="citation_reference" content="&quot;The Lung,&quot; Scientific Foundations, Raven Press, Ltd., New York, Ch. 3.4.11 (1991), Schwartz, pp. 601-615."><meta name="citation_reference" content="Church, &quot;Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-allergic Drugs?,&quot; Agents and Actions, vol. 18, 3/4, pp. 288-293 (1986)."><meta name="citation_reference" content="Church, Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti allergic Drugs , Agents and Actions, vol. 18, 3/4, pp. 288 293 (1986)."><meta name="citation_reference" content="Clegg et al., &quot;Histamine Secretion from Human Skin Slices Induced by Anti-IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol,&quot; Clin Allergy, vol. 15, pp. 321-328 (1985)."><meta name="citation_reference" content="Clegg et al., Histamine Secretion from Human Skin Slices Induced by Anti IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol, Clin Allergy, vol. 15, pp. 321 328 (1985)."><meta name="citation_reference" content="Hamilton et al., &quot;Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals,&quot; Clinical and Experimental Allergy, vol. 24, pp. 955-959 (1994)."><meta name="citation_reference" content="Hamilton et al., Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals, Clinical and Experimental Allergy, vol. 24, pp. 955 959 (1994)."><meta name="citation_reference" content="Ikeda et al., &quot;Effects of Oxatomide and KW-4679 on Acetylcholine-Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands,&quot; Int. Arch. Allergy Immunol., vol. 106, pp. 157-162 (1995)."><meta name="citation_reference" content="Ikeda et al., Effects of Oxatomide and KW 4679 on Acetylcholine Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands, Int. Arch. Allergy Immunol., vol. 106, pp. 157 162 (1995)."><meta name="citation_reference" content="Irani et al., &quot;Mast Cell Heterogeneity,&quot; Clinical and Experimental Allergy, vol. 19, pp. 143-155 (1989)."><meta name="citation_reference" content="Irani et al., Mast Cell Heterogeneity, Clinical and Experimental Allergy, vol. 19, pp. 143 155 (1989)."><meta name="citation_reference" content="Kamei et al. &quot;Effect of Certain Antirallergic Drugs on Experimental Conjunctivitis in Guinea Pigs&quot;, Atarashii Ganka 11(4) pp. 603-605 1994 (month unavailable)."><meta name="citation_reference" content="Kamei et al. Effect of Certain Antirallergic Drugs on Experimental Conjunctivitis in Guinea Pigs , Atarashii Ganka 11(4) pp. 603 605 1994 (month unavailable)."><meta name="citation_reference" content="Kamei et al., &quot;Effect of (Z)-11-[3-(Dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs,&quot; Arzneimittelforschung, vol. 45(9), pp. 1005-1008 (1985)."><meta name="citation_reference" content="Kamei et al., &quot;Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs,&quot; Atarashi Ganka, vol. 11(4), pp. 603-605 (1994) (abstract only)."><meta name="citation_reference" content="Kamei et al., Effect of (Z) 11 3 (Dimethylamino) propylidene 6,11 dihydrodibenz b,e oxepin 2 acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs, Arzneimittelforschung, vol. 45(9), pp. 1005 1008 (1985)."><meta name="citation_reference" content="Kamei et al., Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs, Atarashi Ganka , vol. 11(4), pp. 603 605 (1994) (abstract only)."><meta name="citation_reference" content="Ohsima et al., &quot;Synthesis and Antiallergic Activity of 11-(Aminoalkylidene)-6,11,dihydrodibenz[b,e]oxepin Derivatives,&quot; J. Medicinal Chemistry, vol. 35(11), pp. 2074-1084 (1992)."><meta name="citation_reference" content="Ohsima et al., Synthesis and Antiallergic Activity of 11 (Aminoalkylidene) 6,11,dihydrodibenz b,e oxepin Derivatives, J. Medicinal Chemistry , vol. 35(11), pp. 2074 1084 (1992)."><meta name="citation_reference" content="Pearce et al., &quot;Effect Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin,&quot; Clinical Exp. Immunol.,vol. 17, pp. 437-440 (1974)."><meta name="citation_reference" content="Pearce et al., Effect Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin, Clinical Exp. Immunol., vol. 17, pp. 437 440 (1974)."><meta name="citation_reference" content="Sharif et al., &quot;Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases,&quot; J. of Pharmacology and Experimental Therapeutics, vol. 278(3), pp. 1252-1261 (1996)."><meta name="citation_reference" content="Sharif et al., &quot;Olopatadine (AL-4943A): Pharmacological Profile of a Novel Anti-histaminic/Anti-allergic Drug for Use in Allergic Conjunctivitis,&quot; Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1027 (1996) (abstract only)."><meta name="citation_reference" content="Sharif et al., Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL 4943A), a Novel Drug for Treating Ocular Allergic Diseases, J. of Pharmacology and Experimental Therapeutics, vol. 278(3), pp. 1252 1261 (1996)."><meta name="citation_reference" content="Sharif et al., Olopatadine (AL 4943A): Pharmacological Profile of a Novel Anti histaminic/Anti allergic Drug for Use in Allergic Conjunctivitis, Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1027 (1996) (abstract only)."><meta name="citation_reference" content="Siraganian, &quot;An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine,&quot; Anal. Biochem., vol. 57, pp. 383-394 (1974)."><meta name="citation_reference" content="Siraganian, An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine, Anal. Biochem., vol. 57, pp. 383 394 (1974)."><meta name="citation_reference" content="Spitalny et al., &quot;Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis,&quot; Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 593 (1996) (abstract only)."><meta name="citation_reference" content="Spitalny et al., Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis, Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 593 (1996) (abstract only)."><meta name="citation_reference" content="The Lung, Scientific Foundations, Raven Press, Ltd., New York, Ch. 3.4.11 (1991), Schwartz, pp. 601 615."><meta name="citation_reference" content="Yanni et al., &quot;The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), An Effective Anti-allergic/AntihistamIinic Agent,&quot; Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1028 (1996) (abstract only)."><meta name="citation_reference" content="Yanni et al., The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL 4943A), An Effective Anti allergic/AntihistamIinic Agent, Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1028 (1996) (abstract only)."><meta name="citation_reference" content="Zhang et al., &quot;Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic and Antimuscarinic Activity,&quot; Chirality, vol. 6(8), pp. 631-641 (1994)."><meta name="citation_reference" content="Zhang et al., Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic and Antimuscarinic Activity, Chirality, vol. 6(8), pp. 631 641 (1994)."><meta name="citation_patent_number" content="US:5641805"><meta name="citation_patent_application_number" content="US:08/469,729"><link rel="canonical" href="http://www.google.com/patents/US5641805"/><meta property="og:url" content="http://www.google.com/patents/US5641805"/><meta name="title" content="Patent US5641805 - Topical ophthalmic formulations for treating allergic eye diseases"/><meta name="description" content="Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis."/><meta property="og:title" content="Patent US5641805 - Topical ophthalmic formulations for treating allergic eye diseases"/><meta property="og:type" content="book"/><meta property="og:site_name" content="Google Books"/><meta property="og:image" content="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><link rel="image_src" href="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"/><script>(function(){try{var aa=function(a,b,c,d){d=d||{};d._sn=["cfg",b,c].join(".");window.gbar.logger.ml(a,d)};var g=window.gbar=window.gbar||{},l=window.gbar.i=window.gbar.i||{},m={},n;function _tvn(a,b){var c=parseInt(a,10);return isNaN(c)?b:c}function _tvf(a,b){var c=parseFloat(a);return isNaN(c)?b:c}function _tvv(a){return!!a}function p(a,b,c){(c||g)[a]=b}g.bv={n:_tvn("2",0),r:"",f:".67.",e:"0",m:_tvn("0",1)};
function q(a,b,c){var d="on"+b;if(a.addEventListener)a.addEventListener(b,c,!1);else if(a.attachEvent)a.attachEvent(d,c);else{var f=a[d];a[d]=function(){var a=f.apply(this,arguments),b=c.apply(this,arguments);return void 0==a?b:void 0==b?a:b&&a}}}var s=function(a){return function(){return g.bv.m==a}},ba=s(1),ca=s(2);p("sb",ba);p("kn",ca);l.a=_tvv;l.b=_tvf;l.c=_tvn;l.i=aa;var da=window.gbar.i.i;var t,u,v,w;function ea(a){v=a}function fa(a){var b;if(b=v&&window.encodeURIComponent)b=a.href,b=!b.match(/^http[s]?:\/\/accounts\.google\.[^/]*\/ClearSID/i)&&!b.match(/^http[s]?:\/\/[^/]*\/accounts\/ClearSID/i);if(b=b&&encodeURIComponent(v()))a.href=a.href.replace(/([?&]continue=)[^&]*/,"$1"+b)}function ga(a){window.gApplication&&(a.href=window.gApplication.getTabUrl(a.href))}
function ha(a){var b=document.forms[0].q,c=window.encodeURIComponent&&b&&b.value,b=b&&b.placeholder;c&&c!=b&&(a.href=a.href.replace(/([?&])q=[^&]*|$/,function(a,b){return(b||"&")+"q="+encodeURIComponent(c)}))}n=l.a("")?ga:ha;
function x(a,b,c,d,f,e){var h=document.getElementById(a);if(h){var k=h.style;k.left=d?"auto":b+"px";k.right=d?b+"px":"auto";k.top=c+"px";k.visibility=u?"hidden":"visible";f&&e?(k.width=f+"px",k.height=e+"px"):(x(t,b,c,d,h.offsetWidth,h.offsetHeight),u=u?"":a)}}
var y=[],ia=function(a,b){y.push(b)},ja=function(a){a=a||window.event;var b=a.target||a.srcElement;a.cancelBubble=!0;null==t&&(a=document.createElement(Array.every||window.createPopup?"iframe":"div"),a.frameBorder="0",t=a.id="gbs",a.src="javascript:''",b.parentNode.appendChild(a),q(document,"click",z));var c=b,b=0;"gb3"!=c.className&&(c=c.parentNode);a=c.getAttribute("aria-owns")||"gbi";var d=c.offsetWidth,f=20<c.offsetTop?46:24;document.getElementById("tphdr")&&(f-=3);var e=!1;do b+=c.offsetLeft||
0;while(c=c.offsetParent);var c=(document.documentElement.clientWidth||document.body.clientWidth)-b-d,h,d=document.body,k=document.defaultView;k&&k.getComputedStyle?(d=k.getComputedStyle(d,""))&&(h=d.direction):h=d.currentStyle?d.currentStyle.direction:d.style.direction;h="rtl"==h;if("gbi"==a){for(d=0;k=y[d++];)k();A(null,window.navExtra);h&&(b=c,e=!0)}else h||(b=c,e=!0);u!=a&&z();x(a,b,f,e)},z=function(){u&&x(u,0,0)},A=function(a,b){var c,d=document.getElementById("gbi"),f=a;f||(f=d.firstChild);
for(;b&&(c=b.pop());){var e=d,h=c,k=f;w||(w="gb2");e.insertBefore(h,k).className=w}},ka=function(a,b,c){if((b=document.getElementById(b))&&a){a.className="gb4";var d=document.createElement("span");d.appendChild(a);d.appendChild(document.createTextNode(" | "));d.id=c;b.appendChild(d)}},la=function(){return document.getElementById("gb_70")},ma=function(){return!!u};p("qs",n);p("setContinueCb",ea);p("pc",fa);p("tg",ja);p("close",z);p("addLink",ka);p("almm",A);p("si",la);p("adh",ia);p("op",ma);var B=function(){},C=function(){},F=function(a){var b=new Image,c=D;b.onerror=b.onload=b.onabort=function(){try{delete E[c]}catch(a){}};E[c]=b;b.src=a;D=c+1},E=[],D=0;p("logger",{il:C,ml:B,log:F});var G=window.gbar.logger;var H={},na={},I=[],oa=l.b("0.1",.1),pa=l.a("1",!0),qa=function(a,b){I.push([a,b])},ra=function(a,b){H[a]=b},sa=function(a){return a in H},J={},K=function(a,b){J[a]||(J[a]=[]);J[a].push(b)},ta=function(a){K("m",a)},L=function(a,b){var c=document.createElement("script");c.src=a;c.async=pa;Math.random()<oa&&(c.onerror=function(){c.onerror=null;B(Error("Bundle load failed: name="+(b||"UNK")+" url="+a))});(document.getElementById("xjsc")||document.getElementsByTagName("body")[0]||
document.getElementsByTagName("head")[0]).appendChild(c)},N=function(a){for(var b=0,c;(c=I[b])&&c[0]!=a;++b);!c||c[1].l||c[1].s||(c[1].s=!0,M(2,a),c[1].url&&L(c[1].url,a),c[1].libs&&m.d&&m.d(c[1].libs))},O=function(a){K("gc",a)},P=null,ua=function(a){P=a},M=function(a,b,c){if(P){a={t:a,b:b};if(c)for(var d in c)a[d]=c[d];try{P(a)}catch(f){}}};p("mdc",H);p("mdi",na);p("bnc",I);p("qGC",O);p("qm",ta);p("qd",J);p("lb",N);p("mcf",ra);p("bcf",qa);p("aq",K);p("mdd","");p("has",sa);
p("trh",ua);p("tev",M);var Q=l.b("0.1",.001),R=0;
function _mlToken(a,b){try{if(1>R){R++;var c,d=a,f=b||{},e=encodeURIComponent,h=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&jexpid=",e("17483"),"&srcpg=",e("prop=22"),"&jsr=",Math.round(1/Q),"&ogev=",e("DuLoU966MsKtyATa-YKACA"),"&ogf=",g.bv.f,"&ogrp=",e("1"),"&ogv=",e("1407291699.0"),"&oggv="+e("es_plusone_gc_20140723.0_p0"),"&ogd=",e("com"),"&ogc=",e("LUX"),"&ogl=",e("en")];f._sn&&(f._sn="og."+
f._sn);for(var k in f)h.push("&"),h.push(e(k)),h.push("="),h.push(e(f[k]));h.push("&emsg=");h.push(e(d.name+":"+d.message));var r=h.join("");S(r)&&(r=r.substr(0,2E3));c=r;var Aa=window.gbar.logger._aem(a,c);F(Aa)}}catch(Na){}}var S=function(a){return 2E3<=a.length},va=function(a,b){return b};function T(a){B=a;p("_itl",S,G);p("_aem",va,G);p("ml",B,G);a={};H.er=a}l.a("")?T(function(a){throw a;}):l.a("1")&&Math.random()<Q&&T(_mlToken);I.push(["m",{url:"//ssl.gstatic.com/gb/js/scm_7385cc5883250b43a39405734c1bea59.js"}]);g.mcf("c",{});g.sg={c:""};if(l.a("1")){var wa=l.a("");I.push(["gc",{auto:wa,url:"//ssl.gstatic.com/gb/js/abc/gci_91f30755d6a6b787dcc2a4062e6e9824.js",libs:"googleapis.client:plusone:gapi.iframes"}]);var xa={version:"gci_91f30755d6a6b787dcc2a4062e6e9824.js",index:"",lang:"en"};H.gc=xa;var U=function(a){window.googleapis&&window.iframes?a&&a():(a&&O(a),N("gc"))};p("lGC",U);l.a("1")&&p("lPWF",U)};window.__PVT="";if(l.a("1")&&l.a("1")){var V=function(a){U(function(){K("pw",a);N("pw")})};p("lPW",V);I.push(["pw",{url:"//ssl.gstatic.com/gb/js/abc/pwm_45f73e4df07a0e388b0fa1f3d30e7280.js"}]);var W=[],ya=function(a){W[0]=a},za=function(a,b){var c=b||{};c._sn="pw";B(a,c)},Ba={signed:W,elog:za,base:"https://plusone.google.com/u/0",loadTime:(new Date).getTime()};H.pw=Ba;var X=function(a,b){for(var c=b.split("."),d=function(){var b=arguments;a(function(){for(var a=g,d=0,e=c.length-1;d<e;++d)a=a[c[d]];a[c[d]].apply(a,b)})},f=g,e=0,h=c.length-1;e<h;++e)f=
f[c[e]]=f[c[e]]||{};return f[c[e]]=d};X(V,"pw.clk");X(V,"pw.hvr");p("su",ya,g.pw)};function Ca(){function a(){for(var b;(b=e[h++])&&"m"!=b[0]&&!b[1].auto;);b&&(M(2,b[0]),b[1].url&&L(b[1].url,b[0]),b[1].libs&&m.d&&m.d(b[1].libs));h<e.length&&setTimeout(a,0)}function b(){0<f--?setTimeout(b,0):a()}var c=l.a("1"),d=l.a(""),f=3,e=I,h=0,k=window.gbarOnReady;if(k)try{k()}catch(r){da(r,"ml","or")}d?p("ldb",a):c?q(window,"load",b):b()}p("rdl",Ca);var Da={D:1,H:2,da:3,p:4,W:5,M:6,F:7,g:8,ha:9,U:10,L:11,T:12,S:13,N:14,Q:15,P:16,fa:17,w:18,O:19,ga:20,ea:21,u:22,G:23,ja:24,ka:25,ia:26,A:27,j:28,o:29,k:30,ca:31,Z:32,$:33,J:34,K:35,ba:36,aa:37,Y:38,B:39,R:40,v:41,X:42,V:43,h:48,C:49,I:500},Y=[1,2,3,4,5,6,9,10,11,13,14,28,29,30,34,35,37,38,39,40,41,42,43,48,49,500];var Z=l.b("0.001",1E-4),Ea=l.b("1",1),Fa=!1,Ga=!1;if(l.a("1")){var Ha=Math.random();Ha<=Z&&(Fa=!0);Ha<=Ea&&(Ga=!0)}var Ia=Da,$=null;function Ja(){var a=0,b=function(b,d){l.a(d)&&(a|=b)};b(1,"");b(2,"");b(4,"");b(8,"");return a}
function Ka(a,b){var c=Z,d=Fa,f;f=a;if(!$){$={};for(var e=0;e<Y.length;e++){var h=Y[e];$[h]=!0}}if(f=!!$[f])c=Ea,d=Ga;if(d){d=encodeURIComponent;g.rp?(f=g.rp(),f="-1"!=f?f:"1"):f="1";c=["//www.google.com/gen_204?atyp=i&zx=",(new Date).getTime(),"&oge=",a,"&ogex=",d("17483"),"&ogev=",d("DuLoU966MsKtyATa-YKACA"),"&ogf=",g.bv.f,"&ogp=",d("22"),"&ogrp=",d(f),"&ogsr=",Math.round(1/c),"&ogv=",d("1407291699.0"),"&oggv="+
d("es_plusone_gc_20140723.0_p0"),"&ogd=",d("com"),"&ogl=",d("en"),"&ogc=",d("LUX"),"&ogus=",Ja()];if(b){"ogw"in b&&(c.push("&ogw="+b.ogw),delete b.ogw);var k;f=b;e=[];for(k in f)0!=e.length&&e.push(","),e.push(La(k)),e.push("."),e.push(La(f[k]));k=e.join("");""!=k&&(c.push("&ogad="),c.push(d(k)))}F(c.join(""))}}function La(a){"number"==typeof a&&(a+="");return"string"==typeof a?a.replace(".","%2E").replace(",","%2C"):a}C=Ka;p("il",C,G);var Ma={};H.il=Ma;setTimeout(function(){C(Ia.g)},0);}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var b=window.gbar.i.i;var c=window.gbar;var f=function(d){try{var a=document.getElementById("gbom");a&&d.appendChild(a.cloneNode(!0))}catch(e){b(e,"omas","aomc")}};c.aomc=f;}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{var a=window.gbar;a.mcf("pm",{p:""});}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
(function(){try{window.gbar.rdl();}catch(e){window.gbar&&gbar.logger&&gbar.logger.ml(e,{"_sn":"cfg.init"});}})();
if (window['_OC_timingAction']) {window['_OC_timingAction']('patents_refpage');}</script><style>#gbar,#guser{font-size:13px;padding-top:1px !important;}#gbar{float:left;height:22px}#guser{padding-bottom:7px !important;text-align:right}.gbh,.gbd{border-top:1px solid #c9d7f1;font-size:1px}.gbh{height:0;position:absolute;top:24px;width:100%}#gbs,.gbm{background:#fff;left:0;position:absolute;text-align:left;visibility:hidden;z-index:1000}.gbm{border:1px solid;border-color:#c9d7f1 #36c #36c #a2bae7;z-index:1001}.gb1{margin-right:.5em}.gb1,.gb3{zoom:1}.gb2{display:block;padding:.2em .5em}.gb2,.gb3{text-decoration:none !important;border-bottom:none}a.gb1,a.gb4{text-decoration:underline !important}a.gb1,a.gb2,a.gb3,a.gb4{color:#00c !important}.gbi .gb3,.gbi .gb2,.gbi .gb4{color:#dd8e27 !important}.gbf .gb3,.gbf .gb2,.gbf .gb4{color:#900 !important}a.gb2:hover{background:#36c;color:#fff !important}#gbar .gbz0l{color:#000 !important;cursor:default;font-weight:bold;text-decoration:none !important}
#gbar { padding:.3em .6em !important;}</style></head><body  topmargin="3" marginheight="3"><div id=gbar><nobr><a onclick=gbar.qs(this);gbar.logger.il(1,{t:1}); class=gb1 id=gb_1 href="https://www.google.com/search?sa=N&tab=tw">Search</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:2}); class=gb1 id=gb_2 href="http://www.google.com/search?hl=en&tbm=isch&source=og&sa=N&tab=ti">Images</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:8}); class=gb1 id=gb_8 href="http://maps.google.com/maps?hl=en&sa=N&tab=tl">Maps</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:78}); class=gb1 id=gb_78 href="https://play.google.com/?hl=en&sa=N&tab=t8">Play</a> <a onclick=gbar.qs(this);gbar.logger.il(1,{t:36}); class=gb1 id=gb_36 href="http://www.youtube.com/results?sa=N&tab=t1">YouTube</a> <a onclick=gbar.logger.il(1,{t:5}); class=gb1 id=gb_5 href="http://news.google.com/nwshp?hl=en&tab=tn">News</a> <a onclick=gbar.logger.il(1,{t:23}); class=gb1 id=gb_23 href="https://mail.google.com/mail/?tab=tm">Gmail</a> <a onclick=gbar.logger.il(1,{t:25}); class=gb1 id=gb_25 href="https://drive.google.com/?tab=to">Drive</a> <a class=gb3 href="http://www.google.com/intl/en/options/" onclick="this.blur();gbar.tg(event);return !1" aria-haspopup=true><u>More</u> <small>&#9660;</small></a><div class=gbm id=gbi><a onclick=gbar.logger.il(1,{t:24}); class=gb2 id=gb_24 href="https://www.google.com/calendar?tab=tc">Calendar</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:51}); class=gb2 id=gb_51 href="http://translate.google.com/?hl=en&sa=N&tab=tT">Translate</a><a onclick=gbar.logger.il(1,{t:17}); class=gb2 id=gb_17 href="http://www.google.com/mobile/?hl=en&tab=tD">Mobile</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:10}); class=gb2 id=gb_10 href="http://www.google.com/search?hl=en&tbo=u&tbm=bks&source=og&sa=N&tab=tp">Books</a><a onclick=gbar.logger.il(1,{t:212}); class=gb2 id=gb_212 href="https://wallet.google.com/manage/?tab=ta">Wallet</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:6}); class=gb2 id=gb_6 href="http://www.google.com/search?hl=en&tbo=u&tbm=shop&source=og&sa=N&tab=tf">Shopping</a><a onclick=gbar.logger.il(1,{t:30}); class=gb2 id=gb_30 href="http://www.blogger.com/?tab=tj">Blogger</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:27}); class=gb2 id=gb_27 href="http://www.google.com/finance?sa=N&tab=te">Finance</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:31}); class=gb2 id=gb_31 href="https://plus.google.com/photos?sa=N&tab=tq">Photos</a><a onclick=gbar.qs(this);gbar.logger.il(1,{t:12}); class=gb2 id=gb_12 href="http://www.google.com/search?hl=en&tbo=u&tbm=vid&source=og&sa=N&tab=tv">Videos</a><div class=gb2><div class=gbd></div></div><a onclick=gbar.logger.il(1,{t:66}); href="http://www.google.com/intl/en/options/" class=gb2>Even more &raquo;</a></div></nobr></div><div id=guser width=100%><nobr><span id=gbn class=gbi></span><span id=gbf class=gbf></span><span id=gbe></span><a target=_top id=gb_70 href="https://www.google.com/accounts/Login?service=&continue=http://www.google.com/patents%3Fhl%3Den&hl=en" class=gb4>Sign in</a><div style="display: none"><div class=gbm id=gbd5 aria-owner=gbg5><div class=gbmc><ol id=gbom class=gbmcc></ol></div></div></div></nobr></div><div class=gbh style=left:0></div><div class=gbh style=right:0></div><div role="alert" style="position: absolute; left: 0; right: 0;"><a href="http://www.google.com/patents/us5641805?hl=en&amp;output=html_text" title="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."><img border="0" src="http://www.google.com/images/cleardot.gif"alt="Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader."></a></div><div id="guser"><nobr></nobr></div><div style="clear:both;"></div><div id="gb-top-search-box" class="gb-top-search-box-small gb-reset"><table><tr><td class="logo"><a href="http://www.google.com/patents" class="logo-link"><img class="logo-img" src="/intl/en/images/logos/google_logo_41.png" alt="Go to Google Books Home" height="41"/></a></td><td><form action="http://www.google.com/search" name="f" id="vheadf" method="get"><span id="hf"></span><input type="hidden" name="tbm" value="pts"/><input type="hidden" name="tbo" value="1"/><input type="hidden" name="hl" value="en"/><table><tr><td><div class="inputs"><table><tr><td><div class="text-input"><input type="text" name="q" id="vheadq" class="text" maxlength="2048" size="31" value="" title="Search Patents" accesskey="s" autocomplete="off"/><script>window._OC_autoDir &&window._OC_autoDir('vheadq', 'tia-vheadq');</script></div></td><td><div class="submit-input"><input name="btnG" class="submit" type="submit" value=""/></div></td></tr></table></div></td><td class="col-ext-links"><div class="ext-links"><a href="http://www.google.com/advanced_patent_search">&lt;nobr&gt;Advanced Patent Search&lt;/nobr&gt;</a></div></td></tr></table></form></td></tr></table></div><div class="kd-appbar"><h2 class="kd-appname"><a href="/patents">Patents</a></h2><div class="kd-buttonbar left" id="left-toolbar-buttons"><a id="appbar-write-review-link" href=""></a><a id="appbar-view-print-sample-link" href=""></a><a id="appbar-view-ebook-sample-link" href=""></a><a id="appbar-patents-prior-art-finder-link" href="https://www.google.com/patents/related/US5641805"></a><a id="appbar-patents-discuss-this-link" href="http://www.google.com/url?id=_qVCBAABERAJ&amp;q=http://patents.stackexchange.com/redirect/google-patents%3Fpatent%3DUS5641805&amp;usg=AFQjCNHO0FW1cHM8c4AKTmi37kqaAemw-A" data-is-grant="true"></a><a id="appbar-read-patent-link" href="//docs.google.com/viewer?url=patentimages.storage.googleapis.com/pdfs/US5641805.pdf"></a><a id="appbar-download-pdf-link" href="//patentimages.storage.googleapis.com/pdfs/US5641805.pdf"></a></div><div class="kd-buttonbar right" id="right-toolbar-buttons"></div></div><div id="books-microdata" itemscope=""itemtype="http://schema.org/Book"itemid="http://www.google.com/patents/US5641805" style="display:none"><span itemprop="description">Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal...</span><span itemprop="url">http://www.google.com/patents/US5641805?utm_source=gb-gplus-share</span><span class="main-title" itemprop="name">Patent US5641805 - Topical ophthalmic formulations for treating allergic eye diseases</span><img itemprop="image" src="http://www.google.com/patents?id=&amp;printsec=frontcover&amp;img=1&amp;zoom=1"alt="Patent US5641805 - Topical ophthalmic formulations for treating allergic eye diseases" title="Patent US5641805 - Topical ophthalmic formulations for treating allergic eye diseases"></div><div style="display: none"><ol id="ofe-gear-menu-contents" class="gbmcc"><li class="gbe gbmtc"><a class="gbmt goog-menuitem-content" id="" href="http://www.google.com/advanced_patent_search">Advanced Patent Search</a></li></ol></div><table id="viewport_table" cellpadding="0" style="clear:both" cellspacing="0"><tr><td id="viewport_td"><div class=vertical_module_list_row><div id=intl_patents class=about_content><div id=intl_patents_v><table class="patent-bibdata"><tr><td class="patent-bibdata-heading">Publication number</td><td class="single-patent-bibdata">US5641805 A</td></tr><tr><td class="patent-bibdata-heading">Publication type</td><td class="single-patent-bibdata">Grant</td></tr><tr><td class="patent-bibdata-heading">Application number</td><td class="single-patent-bibdata">US 08/469,729</td></tr><tr><td class="patent-bibdata-heading">Publication date</td><td class="single-patent-bibdata">Jun 24, 1997</td></tr><tr><td class="patent-bibdata-heading">Filing date</td><td class="single-patent-bibdata">Jun 6, 1995</td></tr><tr><td class="patent-bibdata-heading">Priority date<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed."></span></td><td class="single-patent-bibdata">Jun 6, 1995</td></tr><tr><td class="patent-bibdata-heading">Fee status<span class="patent-tooltip-anchor patent-question-icon"data-tooltip-text="The fee status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status or dates listed."></span></td><td class="single-patent-bibdata">Paid</td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Also published as</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/CA2195094A1">CA2195094A1</a>, </span><span class="patent-bibdata-value"><a href="/patents/CA2195094C">CA2195094C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1082367C">CN1082367C</a>, </span><span class="patent-bibdata-value"><a href="/patents/CN1161000A">CN1161000A</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE10299034I1">DE10299034I1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE10299034I2">DE10299034I2</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69622527D1">DE69622527D1</a>, </span><span class="patent-bibdata-value"><a href="/patents/DE69622527T2">DE69622527T2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0799044A2">EP0799044A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/EP0799044B1">EP0799044B1</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996039147A2">WO1996039147A2</a>, </span><span class="patent-bibdata-value"><a href="/patents/WO1996039147A3">WO1996039147A3</a></span></span></td></tr><tr class="patent-bibdata-list-row alternate-patent-number"><td class="patent-bibdata-heading">Publication number</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value">08469729, </span><span class="patent-bibdata-value">469729, </span><span class="patent-bibdata-value">US 5641805 A, </span><span class="patent-bibdata-value">US 5641805A, </span><span class="patent-bibdata-value">US-A-5641805, </span><span class="patent-bibdata-value">US5641805 A, </span><span class="patent-bibdata-value">US5641805A</span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Inventors</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Eiji+Hayakawa%22">Eiji Hayakawa</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Masashi+Nakakura%22">Masashi Nakakura</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22Stella+M.+Robertson%22">Stella M. Robertson</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=ininventor:%22John+Michael+Yanni%22">John Michael Yanni</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Original Assignee</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Alcon+Laboratories,+Inc.%22">Alcon Laboratories, Inc.</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/search?tbo=p&tbm=pts&hl=en&q=inassignee:%22Kyowa+Hakko+Kogyo+Co.+Ltd.%22">Kyowa Hakko Kogyo Co. Ltd.</a></span></span></td></tr><tr class="patent-bibdata-list-row "><td class="patent-bibdata-heading">Export Citation</td><td><span class="patent-bibdata-value-list"><span class="patent-bibdata-value"><a href="/patents/US5641805.bibtex">BiBTeX</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5641805.enw">EndNote</a>, </span><span class="patent-bibdata-value"><a href="/patents/US5641805.ris">RefMan</a></span></span></td></tr><tr class="patent-internal-links"><td colspan=2><span class="patent-bibdata-value"><a href="#backward-citations">Patent Citations</a> (6),</span> <span class="patent-bibdata-value"><a href="#npl-citations">Non-Patent Citations</a> (34),</span> <span class="patent-bibdata-value"><a href="#forward-citations">Referenced by</a> (23),</span> <span class="patent-bibdata-value"><a href="#classifications">Classifications</a> (12),</span> <span class="patent-bibdata-value"><a href="#legal-events">Legal Events</a> (12)</span> </td></tr><tr><td colspan=2 class="patent-bibdata-external-link-spacer-top"></td></tr><tr class="patent-bibdata-external-link-spacer-bottom"></tr><tr><td colspan=2><span class="patent-bibdata-heading">External Links:&nbsp;</span><span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://patft.uspto.gov/netacgi/nph-Parser%3FSect2%3DPTO1%26Sect2%3DHITOFF%26p%3D1%26u%3D/netahtml/PTO/search-bool.html%26r%3D1%26f%3DG%26l%3D50%26d%3DPALL%26RefSrch%3Dyes%26Query%3DPN/5641805&usg=AFQjCNGvOS7IzlhQRgOnpTbXdem-IrbXOA">USPTO</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://assignments.uspto.gov/assignments/q%3Fdb%3Dpat%26pat%3D5641805&usg=AFQjCNHPSMMqw_DAXKmC_uOsqUHcqm3Gfw">USPTO Assignment</a>, </span><span class="patent-bibdata-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://worldwide.espacenet.com/publicationDetails/biblio%3FCC%3DUS%26NR%3D5641805A%26KC%3DA%26FT%3DD&usg=AFQjCNFLTe-hwRQOqsW__SZhm7SqSIUxHA">Espacenet</a></span></span></td></tr><tr class="patent-bibdata-group-spacer"></tr></table><div class="number-and-title"><span class="patent-title"><invention-title mxw-id="PT54167078" lang="EN" load-source="patent-office">Topical ophthalmic formulations for treating allergic eye diseases</invention-title></span><br><span class="patent-number">US 5641805 A</span></div><div class="patent-section patent-abstract-section"><div class="patent-section-header"><span class="patent-section-title">Abstract</span></div><div class="patent-text"><abstract mxw-id="PA37651693" lang="EN" load-source="patent-office"> <div class="abstract">Topical ophthalmic formulations of the invention contain as an active ingredient 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof. The formulations are useful for treating allergic eye diseases such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis.</div>
  </abstract></div></div><div class="patent-section patent-drawings-section"><div class="patent-section-header"><span class="patent-section-title">Images<span class="patent-section-count">(6)</span></span></div><div class="patent-drawings-body"><div class="patent-drawings-carousel"><div class="drawings"><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5641805-0.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5641805-0.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5641805-1.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5641805-1.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5641805-2.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5641805-2.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5641805-3.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5641805-3.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5641805-4.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5641805-4.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div><div class="patent-image"><div class="patent-thumbnail"><a href="//patentimages.storage.googleapis.com/pages/US5641805-5.png"><img class="patent-thumbnail-image" alt="Patent Drawing"src="//patentimages.storage.googleapis.com/thumbnails/pages/US5641805-5.png" /></a></div><div class="patent-thumbnail-caption">&nbsp;</div></div></div></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img" alt="Previous page"src="/googlebooks/images/kennedy/page_left.png"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img" alt="Next page"src="/googlebooks/images/kennedy/page_right.png"width="21" height="21" /></div></div></div><div class="patent-post-drawings"></div><div class="patent-section patent-claims-section"><div class="patent-section-header"><span class="patent-section-title">Claims<span class="patent-section-count">(12)</span></span></div><div class="patent-text"><div mxw-id="PCLM5101926" lang="EN" load-source="patent-office" class="claims">
    <claim-statement>What is claimed is:</claim-statement> <div class="claim"> <div num="1" class="claim">
      <div class="claim-text">1. A method for treating allergic eye diseases in humans comprising stabilizing conjuctival mast cells by topically administering to the eye a composition comprising a therapeutically effective amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz(b,e)oxepin-2-acetic acid or a pharmaceutically acceptable salt thereof.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="2" class="claim">
      <div class="claim-text">2. The method of claim 1 wherein the composition is a solution and the amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from about 0.0001 w/v. % to about 5% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="3" class="claim">
      <div class="claim-text">3. The method of claim 2 wherein the amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from about 0.001 to about 0.2% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="4" class="claim">
      <div class="claim-text">4. The method of claim 3 wherein the amount of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is about 0.1% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="5" class="claim">
      <div class="claim-text">5. The method of claim 1 wherein the 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid, substantially free of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="6" class="claim">
      <div class="claim-text">6. The method of claim 5 wherein the amount of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from about 0.0001 to about 5% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="7" class="claim">
      <div class="claim-text">7. The method of claim 6 wherein the amount of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from about 0.001 to about 0.2% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="8" class="claim">
      <div class="claim-text">8. The method of claim 7 wherein the amount of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is 0.1% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="9" class="claim">
      <div class="claim-text">9. The method of claim 1 wherein the 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is (E)-11-(3-dimethylaminopropylidene) -6,11 -dihydrodibenz[b,e]oxepin-2-acetic acid, substantially free of (Z)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid.</div>
    </div>
    </div> <div class="claim-dependent"> <div num="10" class="claim">
      <div class="claim-text">10. The method of claim 9 wherein the amount of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is from about 0.0001 to about 5% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="11" class="claim">
      <div class="claim-text">11. The method of claim 10 wherein the amount of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydredibenz[b,e]oxepin-2-acetic acid is from about 0.001 to about 0.2% (w/v).</div>
    </div>
    </div> <div class="claim-dependent"> <div num="12" class="claim">
      <div class="claim-text">12. The method of claim 11 wherein the amount of (E)-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid is about 0.1% (w/v).</div>
    </div>
  </div> </div></div></div><div class="patent-section patent-description-section"><div class="patent-section-header"><span class="patent-section-title">Description</span></div><div class="patent-text"><div mxw-id="PDES66990342" lang="EN" load-source="patent-office" class="description">
    <heading>BACKGROUND OF THE INVENTION</heading> <p>1. Field of the Invention</p>
    <p>The present invention relates to topical ophthalmic formulations used for treating allergic eye diseases, such as allergic conjunctivitis, vernal conjunctivitis, vernal keratoconjunctivitis, and giant papillary conjunctivitis. More particularly, the present invention relates to therapeutic and prophylactic topical use of 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid for treating and/or preventing allergic eye diseases.</p>
    <p>2. Description of the Related Art</p>
    <p>As taught in U.S. Pat. Nos. 4,871,865 and 4,923,892, both assigned to Burroughs Wellcome Co. ("the Burroughs Wellcome Patents"), certain carboxylic acid derivatives of doxepin, including 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepine-2-carboxylic acid and 11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepine-2(E)-acrylic acid, have antihistamine and antiasthmatic activity. These two patents classify the carboxylic acid derivatives of doxepin as mast cell stabilizers with antihistaminic action because they are believed to inhibit the release of autacoids (i.e., histamine, serotonin, and the like) from mast cells and to inhibit directly histamine's effects on target tissues. The Burroughs Wellcome Patents teach various pharmaceutical formulations containing the carboxylic acid derivatives of doxepin; Example 8 (I) in both of the patents discloses an ophthalmic solution formulation.</p>
    <p>Although both of the Burroughs Wellcome Patents claim that the variety of pharmaceutical formulations disclosed are effective both for veterinary and for human medical use, neither patent contains an example demonstrating that the carboxylic acid derivatives of doxepin have activity in humans. Example 7 in the Burroughs Wellcome Patents demonstrates antihistamine activity in male guinea pigs and Example G demonstrates anaphylactoid activity in Wistar rats.</p>
    <p>It is now well established, however, that the types of mast cells which exist in rodents are different from those in humans. See, for example, THE LUNG: Scientific Foundations, Raven Press, Ltd., New York, Ch. 3.4.11 (1991). Moreover, mast cell populations exist within the same species that differ in phenotype, biochemical properties, functional and pharmacological responses and ontogeny. These recognized differences in mast cells both between and within species are referred to as mast cell heterogeneity. See for example, Irani et al., "Mast Cell Heterogeneity," Clinical and Experimental Allergy, Vol. 19, pp. 143-155 (1989). Because different mast cells exhibit different responses to pharmacological agents, it is not obvious that compounds claimed to be anti-allergic ("mast cell stabilizers") will have clinical utility in specific mast cell populations. The assumption that mast cells are a homogeneous population and that therefore the effects of anti-allergic drugs observed in experiments in rat mast cells would be predictive of those in human cells is known to be incorrect. Church, "Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-Allergic Drugs?," Agents and Actions, Vol. 18, 3/4, 288-293, at 291 (1986).</p>
    <p>Examples exist in the art in which mast cell stabilizing drugs inhibit only select populations of mast cells. Disodium cromoglycate is an anti-allergic drug whose local effects are believed to be due to inhibition of mast cell degranulation (Church, Agents and Actions, at 288). This drug was shown to inhibit rodent mast cell degranulation. In human trials, 100 μM of the drug inhibited mast cells obtained from bronchoalveolar lavage fluid. In dispersed human lung mast cell preparations, 1000 μM of the drug was required to inhibit only 25% to 33% of histamine release. Finally, histamine release from human skin mast cells was not inhibited at all by disodium cromoglycate. Pearce et al., "Effect of Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin," Clinical Exp. Immunol., Vol. 17, 437-440 (1974); and Clegg et al., "Histamine Secretion from Human Skin Slices Induced by Anti-IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol," Clin. Allergy, Vol. 15, 321-328 (1985). These data clearly indicate that classification of a drug as an anti-allergic does not predict that the drug possess inhibitory effects on all mast cell populations.</p>
    <p>Topical ophthalmic formulations which contain drugs having conjunctival mast cell activity may only need to be applied once every 12-24 hours instead of once every 2-4 hours. One disadvantage to the ophthalmic use of reported anti-allergic drugs which in fact have no human conjunctival mast cell stabilizing activity is an increased dosage frequency. Because the effectiveness of ophthalmic formulations containing drugs which do not have conjunctival mast cell activity stems primarily from a placebo effect, more frequent doses are typically required than for drugs which do exhibit conjunctival mast cell activity.</p>
    <p>U.S. Pat. No. 5,116,863, assigned to Kyowa Hakko Kogyo Co., Ltd., ("the Kyowa patent"), teaches that acetic acid derivatives of doxepin and, in particular, the cis form of the compound having the formula ##STR1## (i.e., Z-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid), have anti-allergic and anti-inflammatory activity.</p>
    <p>The Kyowa patent demonstrates anti-allergic activity and anti-inflammatory activity in Wistar male rats. Medicament forms taught by the Kyowa patent for the acetic acid derivatives of doxepin include a wide range of acceptable carriers; however, only oral and injection administration forms are mentioned. In the treatment of allergic eye disease, such as allergic conjunctivitis, such administration methods require large doses of medicine.</p>
    <p>What is needed are topically administrable drug compounds which have demonstrated stabilizing activity on mast cells obtained from human conjunctiva, the target cells for treating allergic eye diseases. What is also needed are local administration methods for the treatment of allergic eye disease.</p>
    <heading>SUMMARY OF THE INVENTION</heading> <p>The present invention provides a method for treating an allergic eye disease characterized by administering to the eye a topical ophthalmic formulation which contains a therapeutically effective amount of 11-(3-dimethylaminopropylidene) -6,11-dihydrodibenz[b,e]oxepin-2-acetic acid (referred to as "Compound A" hereinafter) or a pharmaceutically acceptable salt thereof. The formulation may contain the cis isomer of Compound A (Z-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid), the trans isomer of Compound A (E-11-(3-dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin-2-acetic acid), or a combination of both the cis and the trans isomers of Compound A, and unless specified otherwise,"11-(3-dimethylaminopropylidene)-6,11 -dihydrodibenz[b,e]oxepin-2-acetic acid" or "Compound A" means the cis isomer, the trans isomer or a mixture of both. "Cis isomer" means the cis isomer substantially free of the trans isomer; "trans isomer" means the trans isomer substantially free of the cis isomer. One isomer is "substantially free" of the other isomer if less than about two percent of the unwanted isomer is present.</p>
    <p>Compound A has human conjunctival mast cell stabilizing activity, and may be applied as infrequently as once or twice a day in some cases. In addition to its mast cell stabilizing activity, Compound A also possesses significant antihistaminic activity. Thus, in addition to a prophylactic effect, Compound A will also have a therapeutic effect.</p>
    <heading>DETAILED DESCRIPTION OF THE INVENTION</heading> <p>Compound A is a known compound and both the cis and the trans isomers of Compound A can be obtained by the methods disclosed in U.S. Pat. No. 5,116,863, the entire contents of which are hereby incorporated by reference in the present specification.</p>
    <p>Examples of the pharmaceutically acceptable salts of Compound A include inorganic acid salts such as hydrochloride, hydrobromide, sulfate and phosphate; organic acid salts such as acetate, maleate, fumarate, tartrate and citrate; alkali metal salts such as sodium salt and potassium salt; alkaline earth metal salts such as magnesium salt and calcium salt; metal salts such as aluminum salt and zinc salt; and organic amine addition salts such as triethylamine addition salt (also known as tromethamine), morpholine addition salt and piperidine addition salt.</p>
    <p>The inhibitory effects of reported anti-allergic, mast cell stabilizing drugs on mast cells obtained from human conjunctiva (the target cells for topical ophthalmic drug preparations claimed useful in treating allergic conjunctivitis) were tested according to the following experimental method. Human conjunctival tissues obtained from organ/tissue donors were weighed and transferred to petri dishes containing RPMI 1640 culture medium supplemented with heat inactivated fetal bovine serum (20%, v/v), L-glutamine (2 mM), penicillin (100 units/ml), streptomycin (100 μg/ml), amphotericin B (2.5 μg/ml) and HEPES (10 mM) and equilibrated overnight at 37° C. (5% CO<sub>2</sub>).</p>
    <p>Post equilibration, tissues were placed in Tyrode's buffer (in mM: 137 NaCl, 2.7 KCl, 0.35 Na H<sub>2</sub> PO<sub>4</sub>, 1.8 CaCl<sub>2</sub>, 0.98 MgCl<sub>2</sub>, 11.9 Na HCO<sub>3</sub>, 5.5 glucose) containing 0.1% gelatin (TGCM) and incubated with 200 U each of collagenase (Type IV) and hyaluronidase (Type I-S) per gram of tissue for 30 minutes at 37° C. Following enzyme digestion, tissues were washed with an equal volume of TGCM over Nitex® filter cloth (Tetko, Briarcliff Manor, N.Y.). Intact tissues were placed in TGCM for further enzymatic digestions.</p>
    <p>The flitrate obtained from each digestion was centrifuged (825 g, 7 minutes) and pelleted cells were resuspended in calcium/magnesium free Tyrode's buffer (TG). Pooled cells from all digestions were centrifuged (825 g, 30 minutes) over a 1.058 g/L Percoll® cushion. Mast cell enriched cell pellets were resuspended and washed in TG buffer. Viability and number of mast cells were determined by vital dye exclusion and toluidine blue 0 staining of the harvested cell suspensions. Mast cell containing preparations were placed in supplemented RPMI 1640 culture medium and allowed to equilibrate at 37° C. prior to challenge with anti-human IgE (goat derived IgG antibody).</p>
    <p>Cell suspensions containing 5000 mast cells were added to TGCM containing tubes and challenged with anti-human IgE. The final volume of each reaction tube was 1.0 mL. Tubes were incubated at 37° C. for 15 minutes post challenge. The release reaction was terminated by centrifugation (500 g, 7 minutes). Supernatants were collected and stored (-20° C.) until mediator analyses.</p>
    <p>Initially, supernatants were analyzed for histamine content by both the automated fluorimetric method described by Siraganian, "An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine," Anal. Biochem., Vol. 57, 383-94 (1974), and a commercially available radioimmunoassay (RIA) system (AMAC, Inc., Westbrook, Me.). Results from these assays were positively correlated (r=0.999): therefore, the remainder of histamine analyses were performed by RIA.</p>
    <p>Each experiment included an anti-human IgE (plus vehicle) positive release control, a spontaneous/vehicle release and a total histamine release control. Total histamine release was determined by treatment with Triton X-100® (0.1%). The experiments also included a non-specific goat IgG control. Test compounds are administered to the mast cell cultures either 1 or 15 minutes before stimulation with anti-human IgE. Inhibition of histamine release resulting from challenge of drug treated mast cells was determined by direct comparison with histamine release from vehicle treated, anti-IgE challenged mast cells using Dunnett's t-test (Dunnett, "A multiple comparison procedure for comparing treatments with a control, " J. Amer. Stat Assoc., Vol. 50, 1096-1121 (1955)). The results are reported in Table 1, below.</p>
    <p>As Table 1 clearly shows, the anti-allergic drugs disodium cromoglycate and nedocromil failed to significantly inhibit human conjunctival mast cell degranulation. In contrast, Compound A (cis isomer) produced concentration-dependent inhibition of mast cell degranulation.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 1______________________________________Compound Effect on Histamine Release from HumanConjunctival Tissue Mast Cells upon anti-Human IgE Challenge.                 TreatmentCompound    Dose (μM)                 (min)      Inhibition (%)______________________________________Cromolyn sodium       1000      15         -15.4       300       15         -6.9       100       15         -1.2       30        15         1.8       10        15         10.6Cromolyn sodium       1000       1         -9.4       300        1         -1.8       100        1         1.2       30         1         0.1       10         1         -0.9Nedocromil sodium       1000      15         7.2       300       15         11.3       100       15         28.2*       30        15         15.2       10        15         9.2       3         15         13.2       1         15         10.7       0.3       15         3.7       0.1       15         8.7Nedocromil sodium       1000       1         -1.1       300        1         4.0       100        1         6.7       30         1         -0.9       10         1         -6.5       3          1         0.8       1          1         4.8       0.3        1         8.8       0.1        1         17.4Compound A  2000      15         92.6*       1000      15         66.7*       600       15         47.5*       300       15         29.6*       100       15         13.0       30        15         -3.9______________________________________ *p &lt; 0.05, Dunnett's ttest</pre>
    
    <p>Dunnett's t-test, is a statistical test which compares multiple treatment groups with one control group. In the assay described above, histamine released from drug treated mast cells are compared to histamine released from the anti-human IgE plus vehicle treated mast cells which serve as the positive control. Statistically significant inhibition is determined using this procedure. The probability level of 0.05 is accepted as the level of significance in biomedical research. Data indicated as significant have a low probability (0.05) of occurring by chance, indicating that the inhibition observed is an effect of the drug treatment.</p>
    <p>The effects of the cis and trans isomers of Compound A on histamine release from human conjunctival tissue mast cells upon anti-human IgE challenge are compared in Table 2. The same experimental method used in Table 1 was used in Table 2. The results in Table 2 indicate that there is no statistically significant difference between the conjunctival mast cell activity of the two isomers at the indicated dose level.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 2______________________________________Isomeric Effect of Compound A on In-Vitro Histamine Releasefrom Human Conjunctival Tissue Mast Cells upon anti-HumanIgE Challenge.                  TreatmentCompound     Dose (μM)                  (min)     Inhibition (%)______________________________________Compound A (cis)        500       15        29.7*∓Compound A (trans)        500       15        26.2*∓______________________________________ *p &lt; 0.05, Dunnett's ttest compared to antiIgE positive control. ∓not significantly different; p &gt; 0.05 Studentized Range comparison of indicated doses</pre>
    
    <p>The topical activity of Compound A was tested in a passive anaphylaxis assay performed in rat conjunctiva. This assay indicates whether a topically applied compound effectively prevents or decreases the local allergic response in the conjunctiva. This assay allows an assessment of bioavailability following topical dosing. Briefly, male Sprague Dawley rats (6/group) were passively sensitized by subconjunctival injection of a rat serum containing IgE specific for ovalbumin (OA). Twenty-four hours post sensitization, test compound prepared in saline (0.9% NaCl) or saline vehicle was applied topically onto the sensitized eye. Twenty (20) minutes after dosing, rats were challenged intravenously via the lateral tail vein with 1.0 ml of a solution containing OA (1.0 mg/ml) and Evans Blue dye (2.5 mg/ml). Thirty (30) minutes post antigen challenge, animals were killed, skin was reflected, and the size of the resulting wheal and the intensity of the extravasated dye were determined. The wheal area multiplied by the dye intensity produced the individual response score. Scores for each group of animals were compared with the scores of the saline treated group using Dunnett's test and are listed in Table 3.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">              TABLE 3______________________________________In-Vivo Effects of Compound A on Passive ConjunctivalAnaphylaxis in Rats                PermeabilityCompound Conc. (%, w/v)                Score (× ± S.D.)                              % Change______________________________________NaCl     0.9         239 ± 22   --Compound B    0.1         133 ± 53*  -55Compound C    0.1         139 ± 36*  -53Compound A    0.1         55 ± 56*@  -86(cis)Compound A    0.1         43 ± 34*@  -81(trans)______________________________________ *p &lt; 0.01, Dunnett's test @p &lt; 0.05, Studentized Range Comparison Procedure, significantly differen from Compounds B and C. Compound B = (Z)11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin2-carboxyic acid Compound C = (Z)11-(3-Dimethylaminopropylidene)-6,11-dihydrodibenz[b,e]oxepin2-acrylic acid</pre>
    
    <p>Compound A may be administered to the eye by means of conventional topical ophthalmic formulations, such as solutions, suspensions or gels. The preferred formulation for topical ophthalmic administration of Compound A is a solution. The solution is administered as eye drops. The preferred form of Compound A in the topical ophthalmic formulations of the present invention is the cis isomer. A general method of preparing the eye drops of the present invention is described below.</p>
    <p>Compound A and an isotonic agent are added to sterilized purified water, and if required, a preservative, a buffering agent, a stabilizer, a viscous vehicle and the like are added to the solution and dissolved therein. The concentration of Compound A is 0.0001 to 5 w/v %, preferably 0.001 to 0.2 w/v %, and most preferably about 0.1 w/v %, based on the sterilized purified water. After dissolution, the pH is adjusted with a pH controller to be within a range which allows the use as an ophthalmologic medicine, preferably within the range of 4.5 to 8.</p>
    <p>Sodium chloride, glycerin or the like may be used as the isotonic agent; p-hydroxybenzoic acid ester, benzalkonium chloride or the like as the preservative; sodium hydrogenphosphate, sodium dihydrogenphosphate, boric acid or the like as the buffering agent; sodium edetate or the like as the stabilizer; polyvinyl alcohol, polyvinyl pyrrolidone, polyacrylic acid or the like as the viscous vehicle; and sodium hydroxide, hydrochloric acid or the like as the pH controller.</p>
    <p>If required, other ophthalmologic chemicals such as epinephrine, naphazoline hydrochloride, berberine chloride, sodium azulenesulfonate, lysozyme chloride, glycyrrhizate and the like may be added.</p>
    <p>The eye drops produced by the above method typically need only be applied to the eyes a few times a day in an amount of one to several drops at a time, though in more severe cases the drops may be applied several times a day. A typical drop is about 30 μl.</p>
    <p>Certain embodiments of the invention are illustrated in the following examples.</p>
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">______________________________________Example 1: Preferred Topical Ophthalmic Solution FormulationIngredient        Concentration (W/V %)______________________________________Compound A.HCl     0.111*Dibasic Sodium Phosphate             0.5(Anhydrous), USPSodium Chloride, USP             0.65Benzalkonium Chloride             0.01Sodium Hydroxide, NF             q.s. pH = 7.0Hydrochloric Acid, NF             q.s. pH = 7.0Purified Water    q.s. 100______________________________________ *0.111% Compound A.HCl is equivalent to 0.1% Compound A</pre>
    
    <p>
      </p> <pre xml:space="preserve" listing-type="tabular">Example 2: Topical Opthalmic Gel FormulationIngredient        Concentration (W/V %)______________________________________Compound A.HCl     0.11*Carbopol 974 P    0.8Disodium EDTA     0.01Polysorbate 80    0.05Benzalkonium Chloride, Solution             0.01 + 5 xsSodium Hydroxide  q.s. pH 7.2Hydrochloric acid q.s. pH 7.2Water for Injection             q.s. 100______________________________________ *0.11% Compound A.HCl is equivalent to 0.1% Compound A</pre>
    
    </div></div></div><div class="patent-section patent-tabular-section"><a id="backward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Cited Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4871865">US4871865</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 7, 1986</td><td class="patent-data-table-td patent-date-value">Oct 3, 1989</td><td class="patent-data-table-td ">Burroughs Wellcome Co.</td><td class="patent-data-table-td ">Tricyclic aromatic compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US4923892">US4923892</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 23, 1989</td><td class="patent-data-table-td patent-date-value">May 8, 1990</td><td class="patent-data-table-td ">Burroughs Wellcome Co.</td><td class="patent-data-table-td ">Doxepin derivatives; antiallergens, antiasthmatics, antihistamines</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US5116863">US5116863</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 2, 1987</td><td class="patent-data-table-td patent-date-value">May 26, 1992</td><td class="patent-data-table-td ">Kyowa Hakko Kogyo Co., Ltd.</td><td class="patent-data-table-td ">Dibenz[b,e]oxepin derivative and pharmaceutical compositions thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0048023A2?cl=en">EP0048023A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Sep 15, 1981</td><td class="patent-data-table-td patent-date-value">Mar 24, 1982</td><td class="patent-data-table-td ">Joel E. Bernstein, M.D.</td><td class="patent-data-table-td ">Composition for treating and preventing irritation of the eyes</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0214779A1?cl=en">EP0214779A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Aug 15, 1986</td><td class="patent-data-table-td patent-date-value">Mar 18, 1987</td><td class="patent-data-table-td ">The Wellcome Foundation Limited</td><td class="patent-data-table-td ">Tricyclic compounds</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP0235796A2?cl=en">EP0235796A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Mar 3, 1987</td><td class="patent-data-table-td patent-date-value">Sep 9, 1987</td><td class="patent-data-table-td ">Kyowa Hakko Kogyo Co., Ltd.</td><td class="patent-data-table-td ">Dibenz [b,e] oxepin derivative and antiallergic and antiinflammatory agent</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="npl-citations"></a><div class="patent-section-header"><span class="patent-section-title">Non-Patent Citations</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th colspan="3"class="patent-data-table-th">Reference</th></tr></thead><tr><td class="patent-data-table-td ">1</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">"<a href='http://scholar.google.com/scholar?q="The+Lung%2C"'>The Lung,</a>" Scientific Foundations, Raven Press, Ltd., New York, Ch. 3.4.11 (1991), Schwartz, pp. 601-615.</td></tr><tr><td class="patent-data-table-td ">2</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Church, "<a href='http://scholar.google.com/scholar?q="Is+Inhibition+of+Mast+Cell+Mediator+Release+Relevant+to+the+Clinical+Activity+of+Anti-allergic+Drugs%3F%2C"'>Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-allergic Drugs?,</a>" Agents and Actions, vol. 18, 3/4, pp. 288-293 (1986).</td></tr><tr><td class="patent-data-table-td ">3</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Church, Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti allergic Drugs , Agents and Actions, vol. 18, 3/4, pp. 288 293 (1986).</td></tr><tr><td class="patent-data-table-td ">4</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Clegg et al., "<a href='http://scholar.google.com/scholar?q="Histamine+Secretion+from+Human+Skin+Slices+Induced+by+Anti-IgE+and+Artificial+Secretagogues+and+the+Effects+of+Sodium+Cromoglycate+and+Salbutanol%2C"'>Histamine Secretion from Human Skin Slices Induced by Anti-IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol,</a>" Clin Allergy, vol. 15, pp. 321-328 (1985).</td></tr><tr><td class="patent-data-table-td ">5</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Clegg et al., Histamine Secretion from Human Skin Slices Induced by Anti IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol, Clin Allergy, vol. 15, pp. 321 328 (1985).</td></tr><tr><td class="patent-data-table-td ">6</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Hamilton et al., "<a href='http://scholar.google.com/scholar?q="Comparison+of+a+New+Antihistaminic+and+Antiallergic+Compound+KW+4679+with+Terfenadine+and+Placebo+on+Skin+and+Nasal+Provocation+in+Atopic+Individuals%2C"'>Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals,</a>" Clinical and Experimental Allergy, vol. 24, pp. 955-959 (1994).</td></tr><tr><td class="patent-data-table-td ">7</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Hamilton et al., Comparison of a New Antihistaminic and Antiallergic Compound KW 4679 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals, Clinical and Experimental Allergy, vol. 24, pp. 955 959 (1994).</td></tr><tr><td class="patent-data-table-td ">8</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ikeda et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+Oxatomide+and+KW-4679+on+Acetylcholine-Induced+Responses+in+the+Isolated+Acini+of+Guinea+Pig+Nasal+Glands%2C"'>Effects of Oxatomide and KW-4679 on Acetylcholine-Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands,</a>" Int. Arch. Allergy Immunol., vol. 106, pp. 157-162 (1995).</td></tr><tr><td class="patent-data-table-td ">9</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ikeda et al., Effects of Oxatomide and KW 4679 on Acetylcholine Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands, Int. Arch. Allergy Immunol., vol. 106, pp. 157 162 (1995).</td></tr><tr><td class="patent-data-table-td ">10</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Irani et al., "<a href='http://scholar.google.com/scholar?q="Mast+Cell+Heterogeneity%2C"'>Mast Cell Heterogeneity,</a>" Clinical and Experimental Allergy, vol. 19, pp. 143-155 (1989).</td></tr><tr><td class="patent-data-table-td ">11</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Irani et al., Mast Cell Heterogeneity, Clinical and Experimental Allergy, vol. 19, pp. 143 155 (1989).</td></tr><tr><td class="patent-data-table-td ">12</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kamei et al. "<a href='http://scholar.google.com/scholar?q="Effect+of+Certain+Antirallergic+Drugs+on+Experimental+Conjunctivitis+in+Guinea+Pigs"'>Effect of Certain Antirallergic Drugs on Experimental Conjunctivitis in Guinea Pigs</a>", Atarashii Ganka 11(4) pp. 603-605 1994 (month unavailable).</td></tr><tr><td class="patent-data-table-td ">13</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kamei et al. Effect of Certain Antirallergic Drugs on Experimental Conjunctivitis in Guinea Pigs , Atarashii Ganka 11(4) pp. 603 605 1994 (month unavailable).</td></tr><tr><td class="patent-data-table-td ">14</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kamei et al., "<a href='http://scholar.google.com/scholar?q="Effect+of+%28Z%29-11-%5B3-%28Dimethylamino%29+propylidene%5D-6%2C11-dihydrodibenz%5Bb%2Ce%5Doxepin-2-acetic+Acid+Hydrochloride+on+Experimental+Allergic+Conjunctivitis+and+Rhinitis+in+Rats+and+Guinea+Pigs%2C"'>Effect of (Z)-11-[3-(Dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs,</a>" Arzneimittelforschung, vol. 45(9), pp. 1005-1008 (1985).</td></tr><tr><td class="patent-data-table-td ">15</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Kamei et al., "<a href='http://scholar.google.com/scholar?q="Effects+of+Certain+Antiallergic+Drugs+on+Experimental+Conjunctivitis+in+Guinea+Pigs%2C"'>Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs,</a>" Atarashi Ganka, vol. 11(4), pp. 603-605 (1994) (abstract only).</td></tr><tr><td class="patent-data-table-td ">16</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kamei et al., Effect of (Z) 11 3 (Dimethylamino) propylidene 6,11 dihydrodibenz b,e oxepin 2 acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs, Arzneimittelforschung, vol. 45(9), pp. 1005 1008 (1985).</td></tr><tr><td class="patent-data-table-td ">17</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Kamei et al., Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs, Atarashi Ganka , vol. 11(4), pp. 603 605 (1994) (abstract only).</td></tr><tr><td class="patent-data-table-td ">18</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Ohsima et al., "<a href='http://scholar.google.com/scholar?q="Synthesis+and+Antiallergic+Activity+of+11-%28Aminoalkylidene%29-6%2C11%2Cdihydrodibenz%5Bb%2Ce%5Doxepin+Derivatives%2C"'>Synthesis and Antiallergic Activity of 11-(Aminoalkylidene)-6,11,dihydrodibenz[b,e]oxepin Derivatives,</a>" J. Medicinal Chemistry, vol. 35(11), pp. 2074-1084 (1992).</td></tr><tr><td class="patent-data-table-td ">19</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Ohsima et al., Synthesis and Antiallergic Activity of 11 (Aminoalkylidene) 6,11,dihydrodibenz b,e oxepin Derivatives, J. Medicinal Chemistry , vol. 35(11), pp. 2074 1084 (1992).</td></tr><tr><td class="patent-data-table-td ">20</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Pearce et al., "<a href='http://scholar.google.com/scholar?q="Effect+Disodium+Cromoglycate+on+Antigen+Evoked+Histamine+Release+in+Human+Skin%2C"'>Effect Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin,</a>" Clinical Exp. Immunol.,vol. 17, pp. 437-440 (1974).</td></tr><tr><td class="patent-data-table-td ">21</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Pearce et al., Effect Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin, Clinical Exp. Immunol., vol. 17, pp. 437 440 (1974).</td></tr><tr><td class="patent-data-table-td ">22</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sharif et al., "<a href='http://scholar.google.com/scholar?q="Characterization+of+the+Ocular+Antiallergic+and+Antihistaminic+Effects+of+Olopatadine+%28AL-4943A%29%2C+a+Novel+Drug+for+Treating+Ocular+Allergic+Diseases%2C"'>Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases,</a>" J. of Pharmacology and Experimental Therapeutics, vol. 278(3), pp. 1252-1261 (1996).</td></tr><tr><td class="patent-data-table-td ">23</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Sharif et al., "<a href='http://scholar.google.com/scholar?q="Olopatadine+%28AL-4943A%29%3A+Pharmacological+Profile+of+a+Novel+Anti-histaminic%2FAnti-allergic+Drug+for+Use+in+Allergic+Conjunctivitis%2C"'>Olopatadine (AL-4943A): Pharmacological Profile of a Novel Anti-histaminic/Anti-allergic Drug for Use in Allergic Conjunctivitis,</a>" Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1027 (1996) (abstract only).</td></tr><tr><td class="patent-data-table-td ">24</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sharif et al., Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL 4943A), a Novel Drug for Treating Ocular Allergic Diseases, J. of Pharmacology and Experimental Therapeutics, vol. 278(3), pp. 1252 1261 (1996).</td></tr><tr><td class="patent-data-table-td ">25</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Sharif et al., Olopatadine (AL 4943A): Pharmacological Profile of a Novel Anti histaminic/Anti allergic Drug for Use in Allergic Conjunctivitis, Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1027 (1996) (abstract only).</td></tr><tr><td class="patent-data-table-td ">26</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Siraganian, "<a href='http://scholar.google.com/scholar?q="An+Automated+Continuous+Flow+System+for+the+Extraction+and+Fluorometric+Analysis+of+Histamine%2C"'>An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine,</a>" Anal. Biochem., vol. 57, pp. 383-394 (1974).</td></tr><tr><td class="patent-data-table-td ">27</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Siraganian, An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine, Anal. Biochem., vol. 57, pp. 383 394 (1974).</td></tr><tr><td class="patent-data-table-td ">28</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Spitalny et al., "<a href='http://scholar.google.com/scholar?q="Olopatadine+Ophthalmic+Solution+Decreases+Itching+and+Redness+Associated+with+Allergic+Conjunctivitis%2C"'>Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis,</a>" Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 593 (1996) (abstract only).</td></tr><tr><td class="patent-data-table-td ">29</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Spitalny et al., Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis, Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 593 (1996) (abstract only).</td></tr><tr><td class="patent-data-table-td ">30</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">The Lung, Scientific Foundations, Raven Press, Ltd., New York, Ch. 3.4.11 (1991), Schwartz, pp. 601 615.</td></tr><tr><td class="patent-data-table-td ">31</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Yanni et al., "<a href='http://scholar.google.com/scholar?q="The+In+Vitro+and+In+Vivo+Ocular+Pharmacology+of+Olopatadine+%28AL-4943A%29%2C+An+Effective+Anti-allergic%2FAntihistamIinic+Agent%2C"'>The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), An Effective Anti-allergic/AntihistamIinic Agent,</a>" Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1028 (1996) (abstract only).</td></tr><tr><td class="patent-data-table-td ">32</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Yanni et al., The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL 4943A), An Effective Anti allergic/AntihistamIinic Agent, Investigative Ophthalmology &amp; Visual Science, vol. 37(3), p. 1028 (1996) (abstract only).</td></tr><tr><td class="patent-data-table-td ">33</td><td class="patent-data-table-td "></td><td class="patent-data-table-td ">Zhang et al., "<a href='http://scholar.google.com/scholar?q="Optically+Active+Analogues+of+Ebastine%3A+Synthesis+and+Effect+of+Chirality+on+Their+Antihistaminic+and+Antimuscarinic+Activity%2C"'>Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic and Antimuscarinic Activity,</a>" Chirality, vol. 6(8), pp. 631-641 (1994).</td></tr><tr><td class="patent-data-table-td ">34</td><td class="patent-data-table-td "><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td ">Zhang et al., Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic and Antimuscarinic Activity, Chirality, vol. 6(8), pp. 631 641 (1994).</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="forward-citations"></a><div class="patent-section-header"><span class="patent-section-title">Referenced by</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Citing Patent</th><th class="patent-data-table-th">Filing date</th><th class="patent-data-table-th">Publication date</th><th class="patent-data-table-th">Applicant</th><th class="patent-data-table-th">Title</th></tr></thead><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6174914">US6174914</a></td><td class="patent-data-table-td patent-date-value">Jun 15, 1999</td><td class="patent-data-table-td patent-date-value">Jan 16, 2001</td><td class="patent-data-table-td ">Alcon Laboratories, Inc.</td><td class="patent-data-table-td ">Method of inhibiting cytokine release from human ocular cells</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6372802">US6372802</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2001</td><td class="patent-data-table-td patent-date-value">Apr 16, 2002</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Aniline disulfide derivatives for treating allergic diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6375973">US6375973</a></td><td class="patent-data-table-td patent-date-value">Jan 24, 2001</td><td class="patent-data-table-td patent-date-value">Apr 23, 2002</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Olopatadine and emedastine and an ophthalmically acceptable polymeric quaternary ammonium compound as a preservative</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6420399">US6420399</a></td><td class="patent-data-table-td patent-date-value">Mar 16, 2000</td><td class="patent-data-table-td patent-date-value">Jul 16, 2002</td><td class="patent-data-table-td ">Alcon Manufacturing, Ltd.</td><td class="patent-data-table-td ">Topical ophthalmic mast cell stabilizers for treating allergic eye disease</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6452052">US6452052</a></td><td class="patent-data-table-td patent-date-value">Jan 31, 2002</td><td class="patent-data-table-td patent-date-value">Sep 17, 2002</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Such as bis-(2-(3-hydroxy-butyrylamido)phenyl)-disulfide; treating allergies of the eyes, nose, skin, ear, gastrointestinal tract, airways or lung and preventing/ treating systemic mastocytosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6492418">US6492418</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2001</td><td class="patent-data-table-td patent-date-value">Dec 10, 2002</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Administering benzamide-disulfide derivative for therapy and prophylaxis of allergic disease of the eye, nose, skin, ear, gastrointestinal tract or lung and manifestations of systemic mastocytosis</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6492552">US6492552</a></td><td class="patent-data-table-td patent-date-value">Apr 25, 2001</td><td class="patent-data-table-td patent-date-value">Dec 10, 2002</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Disulfide derivatives useful for treating allergic diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6500864">US6500864</a></td><td class="patent-data-table-td patent-date-value">May 22, 2002</td><td class="patent-data-table-td patent-date-value">Dec 31, 2002</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Disulfide derivatives useful for treating allergic diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6506802">US6506802</a></td><td class="patent-data-table-td patent-date-value">May 22, 2002</td><td class="patent-data-table-td patent-date-value">Jan 14, 2003</td><td class="patent-data-table-td ">Alcon Universal Ltd.</td><td class="patent-data-table-td ">Disulfide derivatives useful for treating allergic diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US6995186">US6995186</a></td><td class="patent-data-table-td patent-date-value">Jun 19, 2002</td><td class="patent-data-table-td patent-date-value">Feb 7, 2006</td><td class="patent-data-table-td ">Alcon, Inc.</td><td class="patent-data-table-td ">For therapy of allergic or inflammatory disorders of the eye and nose</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7402609">US7402609</a></td><td class="patent-data-table-td patent-date-value">Mar 15, 2005</td><td class="patent-data-table-td patent-date-value">Jul 22, 2008</td><td class="patent-data-table-td ">Alcon, Inc.</td><td class="patent-data-table-td ">Olopatadine formulations for topical administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US7977376">US7977376</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Feb 7, 2007</td><td class="patent-data-table-td patent-date-value">Jul 12, 2011</td><td class="patent-data-table-td ">Novartis Ag</td><td class="patent-data-table-td ">For therapy of allergic or inflammatory disorders of the eye and nose</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8101654">US8101654</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jul 7, 2006</td><td class="patent-data-table-td patent-date-value">Jan 24, 2012</td><td class="patent-data-table-td ">Senju Pharmaceutical Co., Ltd.</td><td class="patent-data-table-td ">Percutaneously absorptive ophthalmic preparation comprising olopatadine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US8399508">US8399508</a></td><td class="patent-data-table-td patent-date-value">Jun 30, 2011</td><td class="patent-data-table-td patent-date-value">Mar 19, 2013</td><td class="patent-data-table-td ">Alcon Pharmaceuticals Ltd.</td><td class="patent-data-table-td ">Olopatadine formulations for topical nasal administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/US20120295967">US20120295967</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">May 18, 2012</td><td class="patent-data-table-td patent-date-value">Nov 22, 2012</td><td class="patent-data-table-td ">Gamache Daniel A</td><td class="patent-data-table-td ">High concentration olopatadine ophthalmic composition</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/EP1033989A1?cl=en">EP1033989A1</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Oct 30, 1998</td><td class="patent-data-table-td patent-date-value">Sep 13, 2000</td><td class="patent-data-table-td ">The University of Utah Research Foundation</td><td class="patent-data-table-td ">Method for reducing mast cell mediated allergic reactions</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2006004757A2?cl=en">WO2006004757A2</a><span class='patent-tooltip-anchor' data-tooltip-text="Cited by examiner"> *</span></td><td class="patent-data-table-td patent-date-value">Jun 27, 2005</td><td class="patent-data-table-td patent-date-value">Jan 12, 2006</td><td class="patent-data-table-td ">Alcon Inc</td><td class="patent-data-table-td ">Topical formulations for treating allergic diseases</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2007007863A1?cl=en">WO2007007863A1</a></td><td class="patent-data-table-td patent-date-value">Jul 7, 2006</td><td class="patent-data-table-td patent-date-value">Jan 18, 2007</td><td class="patent-data-table-td ">Senju Pharma Co</td><td class="patent-data-table-td ">Percutaneously absorptive ophthalmic preparation comprising olopatadine</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2009031682A1?cl=en">WO2009031682A1</a></td><td class="patent-data-table-td patent-date-value">Sep 8, 2008</td><td class="patent-data-table-td patent-date-value">Mar 12, 2009</td><td class="patent-data-table-td ">Kyowa Hakko Kirin Co Ltd</td><td class="patent-data-table-td ">EYE DROP COMPRISING DIBENZO[b,e]OXEPIN DERIVATIVE</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011008923A2?cl=en">WO2011008923A2</a></td><td class="patent-data-table-td patent-date-value">Jul 15, 2010</td><td class="patent-data-table-td patent-date-value">Jan 20, 2011</td><td class="patent-data-table-td ">Alcon Research, Ltd.</td><td class="patent-data-table-td ">Olopatadine nasal spray regimen for children</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011027322A1?cl=en">WO2011027322A1</a></td><td class="patent-data-table-td patent-date-value">Sep 2, 2010</td><td class="patent-data-table-td patent-date-value">Mar 10, 2011</td><td class="patent-data-table-td ">Ranbaxy Laboratories Limited</td><td class="patent-data-table-td ">Extended release dosage form containing olopatadine for oral administration</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2011041640A1?cl=en">WO2011041640A1</a></td><td class="patent-data-table-td patent-date-value">Oct 1, 2010</td><td class="patent-data-table-td patent-date-value">Apr 7, 2011</td><td class="patent-data-table-td ">Alcon Research, Ltd.</td><td class="patent-data-table-td ">Olopatadine compositions and uses thereof</td></tr><tr><td class="patent-data-table-td citation-patent"><a href="/patents/WO2012012264A1?cl=en">WO2012012264A1</a></td><td class="patent-data-table-td patent-date-value">Jul 14, 2011</td><td class="patent-data-table-td patent-date-value">Jan 26, 2012</td><td class="patent-data-table-td ">Alcon Research, Ltd.</td><td class="patent-data-table-td ">Methods and compositions for the treatment of allergy</td></tr></table><div class="patent-section-footer">* Cited by examiner</div></div><div class="patent-section patent-tabular-section"><a id="classifications"></a><div class="patent-section-header"><span class="patent-section-title">Classifications</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th"> </th><th class="patent-data-table-th"> </th></tr></thead><tr><td class="patent-data-table-td ">U.S. Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://www.uspto.gov/web/patents/classification/uspc514/defs514.htm&usg=AFQjCNG3QPK1Vhbpe6jO1mfvD3pMcfCuxA#C514S450000">514/450</a></span></td></tr><tr><td class="patent-data-table-td ">International Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031335000">A61K31/335</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K">A61K</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0037080000">A61P37/08</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0027020000">A61P27/02</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031550000">A61K31/55</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=C07D0313120000">C07D313/12</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61P0027140000">A61P27/14</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031450000">A61K31/45</a></span>, <span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://web2.wipo.int/ipcpub/&usg=AFQjCNER44F5jlVoswCkvW3YEcB5lW4moA#refresh=page&notion=scheme&version=20130101&symbol=A61K0031000000">A61K31/00</a></span></td></tr><tr><td class="patent-data-table-td ">Cooperative Classification</td><td class="patent-data-table-td "><span class="nested-value"><a href="http://www.google.com/url?id=_qVCBAABERAJ&q=http://worldwide.espacenet.com/classification&usg=AFQjCNGs5WqSrPE3A4ZP63zGuM6PRNfEFA#!/CPC=A61K31/00">A61K31/00</a></span></td></tr><tr><td class="patent-data-table-td ">European Classification</td><td class="patent-data-table-td "><span class="nested-value">A61K31/00</span></td></tr></table><div class="patent-section-footer"></div></div><div class="patent-section patent-tabular-section"><a id="legal-events"></a><div class="patent-section-header"><span class="patent-section-title">Legal Events</span></div><table class="patent-data-table"><thead class="patent-data-table-thead"><tr class="patent-data-table"><th class="patent-data-table-th">Date</th><th class="patent-data-table-th">Code</th><th class="patent-data-table-th">Event</th><th class="patent-data-table-th">Description</th></tr></thead><tr><td class="patent-data-table-td patent-date-value">Feb 18, 2014</td><td class="patent-data-table-td ">B1</td><td class="patent-data-table-td ">Reexamination certificate first reexamination</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">THE PATENTABILITY OF CLAIMS 4 AND 8 IS CONFIRMED.CLAIMS 1-3, 5-7 AND 9-12 WERE NOT REEXAMINED.</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Feb 26, 2013</td><td class="patent-data-table-td ">RR</td><td class="patent-data-table-td ">Request for reexamination filed</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20121116</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Sep 19, 2012</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">KYOWA HAKKO KOGYO CO., LTD., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ALCON LABORATORIES, INC., TEXAS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">CORRECTIVE ASSIGNMENT TO CORRECT THE SECOND ASSIGNEE MISSING PREVIOUSLY RECORDED ON  REEL 007892 FRAME 0673. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT;ASSIGNORS:HAYAKAWA, EIJI;NAKAKURA, MASASHI;ROBERTSON, STELLA M.;AND OTHERS;SIGNING DATES FROM 19950601 TO 19950605;REEL/FRAME:029005/0897</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 29, 2008</td><td class="patent-data-table-td ">REMI</td><td class="patent-data-table-td ">Maintenance fee reminder mailed</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 24, 2008</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">12</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Nov 6, 2008</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">KYOWA HAKKO KIRIN CO., LTD., JAPAN</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">MERGER;ASSIGNOR:KYOWA HAKKO KOGYO CO., LTD.;REEL/FRAME:021794/0357</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20081001</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jul 21, 2008</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ALCON RESEARCH, LTD., TEXAS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:021266/0729</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20080101</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ALCON RESEARCH, LTD.,TEXAS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">MERGER;ASSIGNOR:ALCON MANUFACTURING, LTD.;REEL/FRAME:21266/729</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 3, 2004</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">8</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 13, 2001</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ALCON MANUFACTURING, LTD., TEXAS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON LABORATORIES, INC.;REEL/FRAME:011887/0550</span></div><div class="nested-key-value"><span class="nested-key">Effective date: </span><span class="nested-value">20010608</span></div><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ALCON MANUFACTURING, LTD. 6201 SOUTH FREEWAY R&amp;D C</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:ALCON LABORATORIES, INC. /AR;REEL/FRAME:011887/0550</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Dec 22, 2000</td><td class="patent-data-table-td ">FPAY</td><td class="patent-data-table-td ">Fee payment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Year of fee payment: </span><span class="nested-value">4</span></div></td></tr><tr><td class="patent-data-table-td patent-date-value">Aug 18, 1998</td><td class="patent-data-table-td ">CC</td><td class="patent-data-table-td ">Certificate of correction</td><td class="patent-data-table-td "></td></tr><tr><td class="patent-data-table-td patent-date-value">Jun 6, 1995</td><td class="patent-data-table-td ">AS</td><td class="patent-data-table-td ">Assignment</td><td class="patent-data-table-td "><div class="nested-key-value"><span class="nested-key">Owner name: </span><span class="nested-value">ALCON LABORATORIES, INC., TEXAS</span></div><div class="nested-key-value"><span class="nested-key">Free format text: </span><span class="nested-value">ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:HAYAKAWA, EIJI;NAKAKURA, MASASHI;ROBERTSON, STELLA M.;AND OTHERS;REEL/FRAME:007892/0673;SIGNING DATES FROM 19950601 TO 19950605</span></div></td></tr></table><div class="patent-section-footer"></div></div><div class="modal-dialog" id="patent-images-lightbox"><div class="patent-lightbox-controls"><div class="patent-lightbox-rotate-controls"><div class="patent-lightbox-rotation-text">Rotate</div><div class="rotate-icon rotate-ccw-icon"></div><div class="rotate-icon rotate-cw-icon"></div></div><div class="patent-lightbox-index-counter"></div><a class="patent-lightbox-fullsize-link" target="_blank">Original Image</a><div class="patent-drawings-control patent-drawings-next"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_right.png" alt="Next page"width="21" height="21" /></div><div class="patent-drawings-control patent-drawings-prev"><img class="patent-drawings-button-img"src="/googlebooks/images/kennedy/page_left.png" alt="Previous page"width="21" height="21" /></div></div><div class="modal-dialog-content"><div class="patent-lightbox-image-holder"><div class="patent-lightbox-placeholder"></div></div></div></div><script>_OC_initPatentsAtb({image_not_available_html: " Image not available"});</script></div></div></div></td></tr></table><script>(function() {var href = window.location.href;if (href.indexOf('?') !== -1) {var parameters = href.split('?')[1].split('&');for (var i = 0; i < parameters.length; i++) {var param = parameters[i].split('=');if (param[0] == 'focus') {var elem = document.getElementById(param[1]);if (elem) {elem.focus();}}}}})();</script><script>_OC_addFlags({LockSrc:"/books/javascript/lock_4ff636b3d23669b7103f3b3a3a18b4cd.js", Host:"http://www.google.com/", IsBooksRentalEnabled:1, IsWebstoreDisplayCaseEnabled:1, IsObfuscationEnabled:1, IsBrowsingHistoryEnabled:1, IsWebReaderSvgEnabled:0, IsGeoLayerEnabled:1, IsImageModeNotesEnabled:1, IsCopyMenuItemEnabled:1, IsGiftingEnabled:0, IsWebReaderUniversalPaginatorEnabled:0, IsOfflineBubbleEnabled:1, IsReaderEnabledForPlayRequests:1, IsFutureOnSaleVolumesEnabled:1, IsOfflineRestrictedCopyEnabled:1, IsBooksUnifiedLeftNavEnabled:1, IsRestrictedCopyEnabled:1, IsZipitFolderCollectionEnabled:1, IsEndOfSampleRecommendationsEnabled:1, IsRatingsOnBookcardsEnabled:1, IsAdsDisabled:0, IsIframePageDisplayEnabled:0, IsEmbeddedMediaEnabled:1, IsImageModeAnnotationsEnabled:1, IsMyLibraryGooglePlusEnabled:1, IsImagePageProviderEnabled:0, IsBookcardListPriceSmall:0, IsInternalUser:0, IsBooksShareButtonEnabled:0, IsPreOrdersEnabled:0, IsDisabledRandomBookshelves:0, WebstoreDisplayCasePosition:3});_OC_Run({"enable_p13n":false,"add_vol_to_collection_base_url":"http://www.google.com/patents?op=add\u0026sig=ACfU3U2oZW_L__Nn62ggAk4DIOMI2ozQWQ\u0026id=_qVCBAABERAJ","remove_vol_from_collection_base_url":"http://www.google.com/patents?op=remove\u0026sig=ACfU3U0Ol8RjvJADz5se8hUZUM_spgPr1A\u0026id=_qVCBAABERAJ","logged_in":false,"p13n_save_user_settings_url":"http://www.google.com/patents?op=edit_user_settings\u0026sig=ACfU3U2Da3kBJkOiHMY5Xfr1baw7e7TgeA","is_cobrand":false,"sign_in_url":"https://www.google.com/accounts/Login?service=\u0026continue=http://www.google.com/patents%3Fhl%3Den\u0026hl=en","is_play_enabled":true}, {"volume_id":"","is_ebook":true,"volumeresult":{"has_flowing_text":false,"has_scanned_text":true,"can_download_pdf":false,"can_download_epub":false,"is_pdf_drm_enabled":false,"is_epub_drm_enabled":false,"download_pdf_url":"http://www.google.com/patents/download/Topical_ophthalmic_formulations_for_trea.pdf?id=_qVCBAABERAJ\u0026output=pdf\u0026sig=ACfU3U34LFejqQFbOYb0vCyv6G8jhobruA"},"sample_url":"http://www.google.com/patents/reader?id=_qVCBAABERAJ\u0026printsec=frontcover\u0026output=reader\u0026source=gbs_atb_hover","is_browsable":true,"is_public_domain":true}, {});</script><div id="footer_table" style="font-size:83%;text-align:center;position:relative;top:20px;height:4.5em;margin-top:2em"><div style="margin-bottom:8px"><a href=http://www.google.com/><nobr>Google&nbsp;Home</nobr></a> - <a href=//www.google.com/patents/sitemap/><nobr>Sitemap</nobr></a> - <a href=http://www.google.com/googlebooks/uspto.html><nobr>USPTO Bulk Downloads</nobr></a> - <a href=/intl/en/privacy/><nobr>Privacy Policy</nobr></a> - <a href=/intl/en/policies/terms/><nobr>Terms of Service</nobr></a> - <a href=https://support.google.com/faqs/answer/2539193?hl=en><nobr>About Google Patents</nobr></a> - <a href="http://www.google.com/tools/feedback/intl/en/error.html" onclick="try{_OC_startFeedback({productId: '72792',locale: 'en'});return false;}catch(e){}"><nobr>Send Feedback</nobr></a></div><span>Data provided by IFI CLAIMS Patent Services</span><br><span >&copy;2012 Google</span></div> <script type="text/javascript">var gaJsHost = (("https:" == document.location.protocol) ? "https://ssl." : "http://www.");document.write(unescape("%3Cscript src='" + gaJsHost + "google-analytics.com/ga.js' type='text/javascript'%3E%3C/script%3E"));</script><script type="text/javascript">var pageTracker = _gat._getTracker("UA-27188110-1");pageTracker._setCookiePath("/patents/");pageTracker._trackPageview();</script> </body></html>